China’s Clover Biopharmaceuticals has dosed the first volunteers in its COVID-19 vaccine candidate Phase I trials, and is testing it in conjunction with two separate adjuvants, one from GlaxoSmithKline PLC and the other from Dynavax Technologies Corp.
The start of Clover’s first-in-human studies on 19 June brings the total of major vaccine candidates in clinical trials to...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)